Cargando…
New agents in acute myeloid leukemia (AML)
Despite expanding knowledge in the molecular landscape of acute myeloid leukemia (AML) and an increasing understanding of leukemogenic pathways, little has changed in the treatment of AML in the last 40 years. Since introduction in the 1970s, combination chemotherapy consisting of anthracycline and...
Autores principales: | Park, Silvia, Cho, Byung Sik, Kim, Hee-Je |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386889/ https://www.ncbi.nlm.nih.gov/pubmed/32719171 http://dx.doi.org/10.5045/br.2020.S003 |
Ejemplares similares
-
A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML
por: Cho, Byung-Sik, et al.
Publicado: (2010) -
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
por: Cho, Byung-Sik, et al.
Publicado: (2017) -
Clinical features and outcomes of hypocellular acute myeloid leukemia in adults: A Korean AML registry data
por: Song, Ik-Chan, et al.
Publicado: (2021) -
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020) -
Characteristics of DNMT3A mutations in acute myeloid leukemia
por: Park, Dong Jin, et al.
Publicado: (2020)